Questions discussed in this category
Patient is undergoing RT and has already started on a GnRH antagonist. If so, how long after their last fraction would be an appropriate wait time?
For example, anticoagulation for recent, significant PE or dual antiplatelet therapy for recent MI, but requiring urgent procedures such as biopsy of ...
Does your practice differ depending on the disease site?
Patient with extrahepatic cholangiocarcinoma s/p Whipple in 2021 with negative margins and no positive nodes followed by adjuvant chemo with subsequen...
Data are scattered, with some starting concurrent and some starting after SBRT to optimize the priming of the immune system with RT.
How would your recommendation change if the patient has H63 homozygous mutation?
Given the improvement in liver function, what factors should be considered before reinitiating immunotherapy?"
25725249121534122916247721981521071242152371923480
Papers discussed in this category
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Mar 19
Hepatology (Baltimore, Md.), 2023 May 22
Hepatology research : the official journal of the Japan Society of Hepatology, 2025 Jan 15
Investigational new drugs, 2024 Aug 30
Radiother Oncol, 2017 May
Cancer chemotherapy and pharmacology, 2019 Aug 23
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-05-20
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020 Oct 23